ESR1 and breast carcinoma: Another novel tracer, 68Ga-NOTA-RM26, was found to be correlated with both ER expression and menstrual status and to improve the sensitivity and specificity of breast cancer diagnosis to 100 and 90.9%, respectively, in proliferating phase patients (103).